PV-10: Phase I data

Researchers at the Moffitt Cancer Center reported data from 8 melanoma patients in an open-label, U.S. Phase I trial showing that intralesional PV-10 led to significant reductions in melanoma cells in injected tumors and in uninjected bystander tumors 7-14 days after treatment. Additionally, PV-10 led to increases in CD3+, CD4+, CD8+ T cells and natural killer T cells in PBMCs. Patients underwent surgery to remove their melanoma tumors about 7-14 days after treatment with PV-10. Data were presented at the American Association for Cancer Research meeting in San Diego. ...